Titan Pharmaceuticals (NASDAQ:TTNP) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

Titan Pharmaceuticals stock opened at $10.00 on Wednesday. The stock’s 50-day moving average is $5.89 and its 200-day moving average is $6.62. Titan Pharmaceuticals has a 12 month low of $4.24 and a 12 month high of $14.80.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.